Fintel reports that on December 3, 2025, BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform ...

Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.

Amgen has underperformed the Nasdaq over the past year, but analysts are still fairly bullish about the biopharma stock's ...

William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

Amgen (NASDAQ: AMGN) has outperformed the market over the past 15 years by 1.0% on an annualized basis producing an average annual return of 13.12%. Currently, Amgen has a market capitalization of ...

Management has positioned bezuclastinib as a potential alternative to Blueprint Medicines' (BPMT) Ayvakit. This PDGFRα/c-KIT ...

We recently published 8 Stocks Jim Cramer Discussed & Mentioned An Important Quantum Computing Development. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer discussed.

Amgen Inc. (NASDAQ: AMGN) just delivered a strong beat-and-raise quarter. That’s pushed the stock to within striking distance of its 52-week high. That also puts it within striking distance of a new ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not ...